The roles of objective data from individuals in the field of healthcare and medicine have become larger and larger. Medical interventions not based on objective data are often criticized. Recently supported concept is that the data from individuals should be fully analyzed by statistics and informatics, and prevention and treatment of diseases should be based on such results. Medicine based on individual data, i.e. EBM (evidence-based medicine) has become the standard in all the fields of healthcare and medicine.
Because of the rapid progress of computers and machines, large sizes of data (big data) are now available. Human genetic information is described by about 3 billion letters of which about 1 million are different between individuals. The data for those 1 million letters are routinely available, and even the data for 3 billion letters will become available soon for each individual. In the fields other than genetics, large sizes of data are also available because of the development of electronic medical records, electronic journals, internet and omics technologies. By analyzing such large-sale data, we are expected to perform better healthcare and medicine optimized to each individual and also perform more efficient new drug development and drug repositioning.
In the near future, the size of the data will increase even more and the analyses of such data will influence the success or failure of business. We promote our projects, i.e. new drug development and drug repositioning based on a successful model, healthcare system by ICT (information and communication technology), and support of researches by making full use of our abilities and experiences in the data analyses.
Current position: Chairman, StaGen Co. Ltd;
Director of Research Institute for Artificial Intelligence in Medicine;
Director, Gout Foundation of Japan
Naoyuki Kamatani, M.D., Ph.D. graduated from Faculty of Medicine, University of Tokyo in 1973, and was engaged in clinical practice and education in the field of connective-tissue disease, rheumatoid arthritis, gout and genetic diseases associated with metabolism as a clinician, teacher and researcher in University of Tokyo Hospital, Hitachi General Hospital in Hitachi, and Institute of Rheumatology, Tokyo Women’s Medical University. He also worked for Scripps Clinic and Research Foundation from April, 1979 to March, 1982, and published a paper that lead to the development of an anti-leukemic drug cladribine, discovered the first cancer suppressor gene, MTAP and development of personalized anti-cancer therapy targeted at MTAP-deficient cancer cells. From 1998 to 2008, he served as the director of Institute of Rheumatology, Tokyo Women’s Medical University, and supervised a cohort study for rheumatoid arthritis, IORRA, clinical study on pharmacogenomics and clinical development of a new antihyperuricemic and anti-gout drug, febuxostat. He has a lot of international experiences as represented by the fact that he had served as a visiting professor to Department of Internal Medicine, Michigan University from April 1989 to March 1990. He also served as the director of Center for Genomic Medicine (CGM), RIKEN from April 2010 to December 2011, and were involved in GWAS studies for various diseases and traits. He contributed to more than 600 papers.
http://www.ncbi.nlm.nih.gov/pubmed/?term=kamatani+n+%5Bau%5D